La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

MAIA Biotechnology Bilan de santé

Santé financière contrôle des critères 4/6

MAIA Biotechnology possède un total de capitaux propres de $3.2M et une dette totale de $0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont $12.0M et de $8.9M.

Informations clés

Ratio d'endettement

US$0

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	US$11.58m
Fonds propres	US$3.16m
Total du passif	US$8.86m
Total des actifs	US$12.02m

Mises à jour récentes de la santé financière

Recent updates

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de MAIA ( $12.0M ) dépassent ses passifs à court terme ( $3.5M ).

Passif à long terme: Les actifs à court terme de MAIA ( $12.0M ) dépassent ses passifs à long terme ( $5.3M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: MAIA est sans dette.

Réduire la dette: MAIA n'avait aucune dette il y a 5 ans.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: MAIA dispose de moins d'un an de piste de trésorerie sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: MAIA dispose de moins d'un an de marge de trésorerie si le flux de trésorerie disponible continue de diminuer à un taux historique de 39.2 % chaque année

MAIA Biotechnology Bilan de santé

Santé financière contrôle des critères 4/6

Informations clés

Mises à jour récentes de la santé financière

NYSE American Believes MAIA Biotechnology Not in Compliance with Listing Standards

Recent updates

MAIA Biotechnology, Inc. to Present New Phase 2 Clinical Trial Data at the H.C. Wainwright 26th Annual Global Investment Conference

New major risk - Financial position

Maia Biotechnology Announces New Updates from Phase 2 Trial of Novel Cancer Treatment Agent

Maia Biotechnology Reveals New Clinical Data Showing Thio’s Strong Efficacy in Non-Small Cell Lung Cancer

New major risk - Share price stability

MAIA Biotechnology, Inc. announced a financing transaction

MAIA Biotechnology, Inc. announced that it expects to receive $0.664994 million in funding

MAIA Biotechnology, Inc., Annual General Meeting, May 24, 2024

MAIA Biotechnology, Inc. announced that it expects to receive $1.327985 million in funding

MAIA Biotechnology, Inc. Appoints Saadettin Kilickap to its Scientific Advisory Board

MAIA Biotechnology, Inc. Announces Positive Efficacy Data for Third-Line Treatment in its Phase 2 THIO-101 Clinical Trial Evaluating THIO Sequenced with CPI Cemiplimab in Advanced NSCLC

MAIA Biotechnology, Inc. Completes Enrollment in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer

MAIA Biotechnology, Inc. has filed a Follow-on Equity Offering in the amount of $1.445 million.

MAIA Biotechnology, Inc. Announces Publication in Nature Communications on Positive Effects of THIO for Potential Treatment of Small Cell Lung Cancer

Maia Biotechnology, Inc. Announces Publication of International Pct Patent Application Covering Anticancer Telomere-Targeting Compounds

MAIA Biotechnology, Inc. Provides Positive Phase 2 Clinical Updates for Lead Anticancer Agent and Outlines Targeted Milestones for 2024

MAIA Biotechnology, Inc. Announces Dose Selection in Thio-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer

New major risk - Shareholder dilution

NYSE American Believes MAIA Biotechnology Not in Compliance with Listing Standards

MAIA Biotechnology, Inc. Announces 100% Disease Control in Second-Line Non-Small Cell Lung Cancer Demonstrating Impressive Positive Preliminary Efficacy Data for Ongoing THIO-101 Phase 2 Trial

MAIA Biotechnology, Inc. Reveals New Data Showing THIO's Potent Anticancer Activity in Aggressive Pediatric Brain Cancer

MAIA Biotechnology, Inc. Announces Potent Anticancer Activity of THIO in Gliomas

MAIA Biotechnology, Inc. Announces FDA Clearance of IND Application for THIO, a First-in-Class Telomere Targeting Agent for the Treatment of Non-Small Cell Lung Cancer

MAIA Biotechnology, Inc. (NYSEAM:MAIA) announces an Equity Buyback for $0.8 million worth of its shares.

New major risk - Revenue and earnings growth

MAIA Biotechnology, Inc. Provides Updates for THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer

MAIA Biotechnology, Inc. Reports Updates on Preliminary Survival Data for Thio-101 Phase 2 Trial for Advanced Non-Small Cell Lung Cancer

MAIA Biotechnology, Inc. Files Second Patent for New Telomere-Targeting Molecules Program

Lead Independent Director recently bought US$300k worth of stock

MAIA Biotechnology, Inc. Announces it Intends to Initiate its Second Phase 2 Go-To-Market Trial Evaluating THIO

MAIA Biotechnology, Inc. Holds Successful Pre-IND Meeting with FDA for Planned US Expansion of THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer

MAIA Biotechnology, Inc. Expands Phase 2 THIO-101 Trial to Europe

High number of new and inexperienced directors

MAIA Biotechnology, Inc. has completed an IPO in the amount of $10 million.

High number of new and inexperienced directors

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines